• Record sales of A$4.2 million for HY26, up 5% on HY25
• FDA approval of IMM-529 Investigational New Drug application for Phase 2 clinical trial in Clostridioides difficile infection
• New US Department of Defense award to develop two new oral therapeutics targeting Campylobacter and Shigella

Immuron Ltd has reported a loss for the half-year ended 31 December 2025 of A$1,919,074, down 23% from the prior period. The group's net assets increased to A$13,076,439 compared with A$8,069,055 at 30 June 2025, including cash reserves of A$9,995,328. Revenue from ordinary activities for the half-year was A$4,184,357, up 5% on the prior year. Key highlights include record sales of A$4.2 million for HY26, FDA approval of the IMM-529 Investigational New Drug application for a Phase 2 clinical trial in Clostridioides difficile infection, and a new US Department of Defense award to develop two new oral therapeutics targeting Campylobacter and Shigella. The company also launched its PROIBS® product for Irritable Bowel Syndrome in Australia.

Based on the estimated market size, anticipated payer restrictions, pricing, and competition, the base case yearly revenue for IMM-529 is projected at US$400 million.